Guest guest Posted January 17, 2008 Report Share Posted January 17, 2008 Dear Forum, As per the news from AIDSmed, we’re now in a countdown of days until the U.S. Food and Drug Administration (FDA) approves the first antiretroviral of 2008: Etravirine (also known as TMC125). Scheduled to be approved by the end of this week, etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI)—a “non-nuke”—with a very important twist. It works against HIV strains resistant to Efavirenz and Nevirapine, effectively becoming the first NNRTI to break the cross-resistance barrier that has long plagued this class of drugs. Should the FDA approve etravirine, it will be the third new antiretroviral approved in the last six months. The string of recent approvals after the safety profile examination is likely to have a significant impact on the lives of thousands of people who are heavily treatment-experienced and in desperate need of new treatment options. Dr Diwakar Tejaswi MBBS(Gold Medalist); MCH; FCCP; Ph.D. Medical Director International Health Organization www.ihousa.org +91-9835078298 e-mail: diwakartejaswi@... Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.